Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001152314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
31/08/2026
Date registered
Help: Date registered
16/09/2026
Date last updated
Help: Date last updated
16/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
16/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Implementing and evaluating Ultraviolet-C mobile phone sanitisation for infection control in the intensive care unit.
Scientific title
The acceptability, sustainability, and perceived utility of Ultraviolet-C phone sanitisation as a supplementary infection control measure used by healthcare workers in the intensive care unit.
Additional trial identifiers [1] 318311 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records
This study is a follow-up study of these previous studies: ACTRN12625001309471; ACTRN12626000431325; ACTRN12626000428369

Health condition
Health condition(s) studied:
Infection control 343443 0
Condition category
Condition code
Infection 339533 339533 0 0
Studies of infection and infectious agents
Public Health 339534 339534 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
A Glissner Cleanphone Ultraviolet-C (UV-C) device will be implemented in a prominent location in the intensive care unit for healthcare workers to self-administer cleaning of their mobile phones. This device applies UV-C radiation to the full 360-degree surface of mobile phones and is a touchless device, meaning no cross-contamination with clean hands. The device is 30cm tall, 26cm wide, and 14cm deep, making it portable and feasible to implement in clinical environments. Furthermore, this device uses an ultra-rapid cleaning time of only 10-seconds per application.

Participants can use the device as often as they like throughout the implementation period and will be encouraged to do so via informational posters placed in the intensive care unit, and communication via meetings, emails, and in-services. Each Glissner Cleanphone device has been retrofitted with a magnetic counter which will record the number of times the device is utilised. This data will be downloaded from the device by the research team after the first 48 hours of implementation, and then weekly to track the amount of device usage over time, and map trends of acceptability, sustainability, and perceived utility. It is anticipated that the overall duration of implementation will be approximately 3-months

This study will employ an iterative quality improvement methodology with the Plan-Do-Study-Act (PDSA) method used as the overarching implementation process. The barriers and facilitators of behaviour change and implementation which were identified through a previous staff survey will inform the preliminary iterative cycles of the PDSA method. Acceptability, sustainability, and perceived utility will be measured following the first PDSA cycle by a follow-up staff survey.
Intervention code [1] 335207 0
Treatment: Devices
Intervention code [2] 335278 0
Treatment: Other
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346716 0
Acceptability of Ultraviolet-C mobile phone sanitisation in the intensive care unit
Timepoint [1] 346716 0
48-hours and then weekly post-implementation, for an overall duration of approximately 3-months.
Secondary outcome [1] 467148 0
Sustainability of Ultraviolet-V mobile sanitisation in the intensive care unit.
Timepoint [1] 467148 0
2-4 weeks post-implementation commencement.
Secondary outcome [2] 467149 0
Perceived utility of Ultraviolet-V mobile sanitisation in the intensive care unit.
Timepoint [2] 467149 0
2-4 weeks post-implementation commencement.

Eligibility
Key inclusion criteria
Adult (greater than or equal to 18 years of age) healthcare workers within the intensive care unit at The Prince Charles Hospital and St Andrew’s War Memorial Hospital.

Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Individuals who do not wish to be part of the study / do not provide consent.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/02/2027
Actual
Date of last participant enrolment
Anticipated
1/05/2027
Actual
Date of last data collection
Anticipated
1/05/2027
Actual
Sample size
Target
50
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 322871 0
Hospital
Name [1] 322871 0
The Prince Charles Hospital
Country [1] 322871 0
Australia
Funding source category [2] 322872 0
Hospital
Name [2] 322872 0
St Andrews War Memorial Hospital
Country [2] 322872 0
Australia
Primary sponsor type
Hospital
Name
The Prince Charles Hospital
Address
Country
Australia
Secondary sponsor category [1] 325799 0
Hospital
Name [1] 325799 0
St Andrews War Memorial Hospital
Address [1] 325799 0
Country [1] 325799 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321306 0
Metro North Health Human Research Ethics Committee
Ethics committee address [1] 321306 0
Ethics committee country [1] 321306 0
Australia
Date submitted for ethics approval [1] 321306 0
25/08/2026
Approval date [1] 321306 0
Ethics approval number [1] 321306 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153302 0
Mr Matthew Linnane
Address 153302 0
The Prince Charles Hospital, Rode Rd, Chermside, QLD, 4032
Country 153302 0
Australia
Phone 153302 0
+61 407755819
Fax 153302 0
Email 153302 0
[email protected]
Contact person for public queries
Name 153303 0
Matthew Linnane
Address 153303 0
The Prince Charles Hospital, Rode Rd, Chermside, QLD, 4032
Country 153303 0
Australia
Phone 153303 0
+61 407755819
Fax 153303 0
Email 153303 0
[email protected]
Contact person for scientific queries
Name 153304 0
Matthew Linnane
Address 153304 0
The Prince Charles Hospital, Rode Rd, Chermside, QLD, 4032
Country 153304 0
Australia
Phone 153304 0
+61 407755819
Fax 153304 0
Email 153304 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.